Gan & Lee Pharmaceuticals Co., Ltd.SSE: 603087

(603087)"Gan & Lee Pharmaceuticals"Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Pre-filled Pen) in El Salvador

· Issued by Gan & Lee Pharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 603087 · · 2 pages · Chinese

Summary by 6ix AI

Gan & Lee Pharmaceuticals Co., Ltd. has announced the acquisition of pharmaceutical registration approval for Insulin Glargine Injection in El Salvador, allowing them to sell this product in the country. The announcement includes details about the drug, its indications for diabetes treatment, and its characteristics as a long-acting insulin. The company also highlights potential risks related to market demand, policy changes, and competition that may affect sales in El Salvador.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/603087gan-and-lee-pharmaceuticalsannouncement-on-acquisition-of-pharmaceutical-registration-approval-for-insulin-glargine-injection-pre-filled-pen-in-el-salvador

Release

Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Pre-filled Pen) in El Salvador

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Gan & Lee Pharmaceuticals Co., Ltd. on 6ix

Story so far

Earlier from Gan & Lee Pharmaceuticals

Later from Gan & Lee Pharmaceuticals

All Gan & Lee Pharmaceuticals news releases